GSK Urges 3rd Circ. To Nix $121M Damages In Paxil Row
GlaxoSmithKline PLC has defended its push for the Third Circuit to vacate about $121 million in damages against the company, saying that the award is based on an unqualified expert witness...To view the full article, register now.
Already a subscriber? Click here to view full article